These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8970213)

  • 1. Challenges for licensure of new diphtheria, tetanus, acellular pertussis (DTaP) combination vaccines: point.
    Granoff DM
    Pediatr Infect Dis J; 1996 Dec; 15(12):1069-70. PubMed ID: 8970213
    [No Abstract]   [Full Text] [Related]  

  • 2. Challenges for licensure of new diphtheria, tetanus toxoid, acellular pertussis (DTaP) combination vaccines: counterpoint.
    Edwards KM; Decker MD
    Pediatr Infect Dis J; 1996 Dec; 15(12):1070-3. PubMed ID: 8970214
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
    Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in two-, four- and six-month-old infants.
    Pichichero ME; Latiolais T; Bernstein DI; Hosbach P; Christian E; Vidor E; Meschievitz C; Daum RS
    Pediatr Infect Dis J; 1997 Sep; 16(9):863-70. PubMed ID: 9306481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
    Lagos R; Kotloff K; Hoffenbach A; San Martin O; Abrego P; Ureta AM; Pines E; Blondeau C; Bailleux F; Levine MM
    Pediatr Infect Dis J; 1998 Apr; 17(4):294-304. PubMed ID: 9576383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA approval of a fourth acellular pertussis vaccine for use among infants and young children.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1998 Nov; 47(43):934-6. PubMed ID: 9822368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and haemophilus B conjugate vaccine and guidance for use in infants and children.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(39):1079-80. PubMed ID: 18830213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA approval of a second acellular pertussis vaccine for use among infants and young children.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Feb; 46(5):110-1. PubMed ID: 9045038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine.
    Daley MF; Yih WK; Glanz JM; Hambidge SJ; Narwaney KJ; Yin R; Li L; Nelson JC; Nordin JD; Klein NP; Jacobsen SJ; Weintraub E
    Vaccine; 2014 May; 32(25):3019-24. PubMed ID: 24699471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined, (PEDIARIX) for use in infants.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2003 Mar; 52(10):203-4. PubMed ID: 12653460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
    Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of acellular pertussis-tetanus-diphtheria vaccines and whole-cell pertussis-tetanus-diphtheria vaccines in infancy.
    Korkmaz HA; Aydin A; Unal B
    Paediatr Int Child Health; 2014 Aug; 34(3):198-202. PubMed ID: 24621240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
    Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
    Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA approval of a Haemophilus b Conjugate Vaccine combined by reconstitution with an acellular pertussis vaccine.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1996 Nov; 45(45):993-5. PubMed ID: 9005308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age.
    Carlsson RM; Claesson BA; Selstam U; Fagerlund E; Granström M; Blondeau C; Hoffenbach A
    Pediatr Infect Dis J; 1998 Nov; 17(11):1026-33. PubMed ID: 9849987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined, reduced-antigen content tetanus, diphtheria, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization in individuals aged 10-64 years in the US.
    Plosker GL
    BioDrugs; 2009; 23(4):253-67. PubMed ID: 19697967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Priming effect, immunogenicity and safety of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey.
    Hoppenbrouwers K; Kanra G; Roelants M; Ceyhan M; Vandermeulen C; Yurdakök K; Silier T; Dupuy M; Pehlivan T; Ozmert E; Desmyter J
    Vaccine; 1999 Feb; 17(7-8):875-86. PubMed ID: 10067694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
    MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations.
    Schmitt HJ; Zepp F; Müschenborn S; Sümenicht G; Schuind A; Beutel K; Knuf M; Bock HL; Bogaerts H; Clemens R
    Eur J Pediatr; 1998 Mar; 157(3):208-14. PubMed ID: 9537487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.